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Highlights: 
- Quantitative LC-ESI-MS/MS analysis of anabolic steroids and hormones in 
wastewater 
- Determination of 17 steroids and hormones at ng L-1 level in wastewater 
- Nine endogenous hormones quantified in 24-h composite wastewater samples in 
Australia (3-104 mg day
-1
1000 individuals
-1
) 
- The anabolic steroid stanozolol detected in a wastewater influent sample 
 
Abstract 
Anabolic-androgenic steroids are synthetic compounds prohibited due to their 
performance enhancing characteristics. The use of these substances is known to cause health-
related issues, which highlights the importance of being able to evaluate the scale of 
consumption by the general population. However, most available research on the analysis of 
anabolic steroids is focussed on animals and athletes in connection with doping. The potential 
of wastewater-based epidemiology as an intelligence tool for the assessment of community 
level use of anabolic steroids is presented herein. A liquid chromatography tandem mass 
spectrometry method was developed for the analysis of ten anabolic-androgenic steroids and 
14 endogenous hormones in influent wastewater. The validated method was applied to 
sixteen 24-hour composite wastewater influent samples that were collected over a period of 
five years from two wastewater treatment plants in Queensland, Australia. Nine investigated 
compounds were found to be present at concentrations between 14-611 ng L
-1
 which 
translated into 3-104 mg excreted per 1000 individuals per day. It was concluded that the 
developed analytical method is suitable for the analysis of AAS in wastewater matrix. 
Additionally, both the inclusion of metabolites and further investigation into deconjugation 
by enzymatic hydrolysis would aid in understanding and evaluating community anabolic 
steroid use. For the first time, this study presents the application of wastewater-based 
epidemiology on anabolic-androgenic steroids in Australia. 
 
Keywords: Anabolic-androgenic steroids, Endogenous hormones, Wastewater analysis, LC-
MS/MS, Solid-phase extraction 
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1. Introduction 
 
Exogenous anabolic-androgenic steroids (AAS) are synthetically derived compounds 
structurally related to the male hormone testosterone. Due to their muscle growth and 
strength-enhancing properties, they are known to be misused among bodybuilders and other 
athletes
1,2
. Several complications are associated with the use of AAS, including serious 
health-related problems such as heart failure and hypertrophy, as well as major mood 
disorders accompanied by violent and aggressive behaviour
3-5
. These substances are 
prohibited by the World Anti-Doping Agency (WADA) because of their performance-
enhancing properties
6
 and are classified as Schedule 4 substances in the Poisons Standard 
under The Therapeutic Goods Act 1989 in Australia
7
. In addition, AAS could potentially be 
harmful to wildlife in receiving environments, if released as endocrine disrupting chemicals, 
as demonstrated for related hormones
8
. Therefore, the ability to detect, identify and quantify a 
broad range of AAS in wastewater would assist in evaluating human consumption as well as 
potential environmental exposure from the release of wastewater effluents. 
 Most available research on AAS analysis has focused on biological matrices such as 
animal or human urine, blood, plasma and hair, often in the context of doping. In these cases, 
analysis is often conducted on biological samples of individuals and usually on professional, 
‘in-competition’ athletes9-16. For doping control analyses, WADA utilises gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS)
17
, which is 
costly and labour-intensive due to hydrolysis and derivatisation steps. More commonly used 
and arguably more flexible techniques for measuring a large range of doping compounds are 
gas chromatography (GC) or liquid chromatography (LC) coupled to either high-resolution 
mass spectrometry (HRMS) or tandem mass spectrometry (MS/MS)
18,19
. The latter has the 
advantage of avoiding complicating derivatisation steps. However, one of the main 
challenges associated with the detection and identification of illicit drug residues, especially 
in wastewater, is the limited information available on their human pharmacokinetic profiles 
and hence the expected target metabolites of some parent analytes
20
. 
 Wastewater-based epidemiology (WBE) is a non-invasive technique that can provide 
spatial and temporal information on the use of and exposure to chemicals within the general 
population
19,21,22
. It has previously been applied to detect and quantify chemicals such as 
prescription, over-the-counter and illicit drugs, personal care products and environmental 
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contaminants in wastewater samples collected from the influent of wastewater treatment 
plants (WWTPs) and has been used for monitoring purposes
23-28
. WBE has the potential for 
being an intelligence gathering tool for authorities
25
 and data can be compared nationally and 
internationally for prevention and rehabilitation purposes
23,29-31
. For the successful 
application of WBE, the selection of the most suitable biomarker for analysis is pivotal. 
There are multiple factors to take into consideration which include stability (e.g., in-sewer 
and in-sample)
32
, transformation due to microbial activity
33
, specificity to compound of 
interest and human metabolism
21,34
. 
One clinical study investigated multiple AAS and showed that most are excreted in their 
conjugated form
35
. Nevertheless, it has also been demonstrated that conjugated hormones can 
be deconjugated by acid-catalysed solvolysis
36
. As wastewater samples are often acidified 
after collection
25,37
, this might have an impact on the occurrence of free steroids and 
hormones in these sample matrices. 
The aim of this work was to further investigate the application of WBE for the assessment 
of AAS use at a community level. Quantitative LC-MS/MS methods to simultaneously 
determine AAS, hormones and metabolites were developed, optimised and validated. The 
validated methodology was applied to sampling campaigns in two catchments; i) for four 
days during a body building event and ii) in an urban centre of more than 100,000 inhabitants 
over a time-period of five years with one sample per season. This is the first study to focus on 
AAS in Australian wastewater and provides an important reference point for future WBE 
studies on a global level. 
 
2. Experimental 
 
2.1. Materials, chemicals and reagents 
 
A detailed account of materials, chemicals and reagents used in the experimental can be 
found in the Supplementary Information (S.I.). Compounds of interest are shown in Table 1. 
5α-dihydrotestosterone-D3 (5α-DHT-D3) 100 µg mL
-1
 in methanol, androstene-3,17-dione-
2,3,4-
13
C3 (99.9%) 100 µg mL
-1
 in acetonitrile and dehydroepiandrosterone-D5 (DHEA-D5) 
100 µg mL
-1
 in methanol were purchased from Cerilliant (Round Rock, TX, USA). 
Cambridge Isotope Laboratories, Inc. (Andover, MA, USA) supplied the two isotopically 
labelled standard solutions 19-nortestosterone (nandrolone) (16,16,17-D3, 98%) 100 µg mL
-1
 
in methanol and testosterone (16,16,17-D3, 98%) 100 µg mL
-1
 in methanol. Epitestosterone-
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D3 was purchased from the National Measurement Institute (NMI) (North Ryde, NSW, AU). 
Lichrosolv grade methanol was added (by weight using a five-digit balance and accounting 
for specific gravity) to certified reference materials that were received as powders to prepare 
stock solutions. Stock solutions of all analytical standards (1000 µg mL
-1
 native standards 
and 100 µg mL
-1
 isotopically-labelled standards) were used to prepare working standard 
solutions in Lichrosolv grade methanol with concentrations of 10 µg mL
-1
 and 100 µg L
-1
, 
which were subsequently stored at -20 
o
C in the dark to minimise degradation. Water was 
purified to 18.2 MΩ cm-1 using a Milli-Q ultrapure water system and filtered using a 0.22 µm 
mesh (Millipore, Bedford, USA). 
 
2.2. Sample collection 
 
 Twenty four-hour composite samples of wastewater influent were collected by refrigerated 
autosamplers (4 
o
C) operating in flow proportional mode at the inlet of two WWTPs in 
Queensland, Australia. Samples (see 2.7.) were collected in high-density polyethylene 
(HDPE) bottles that had been pre-cleaned with 2 × 4 mL aliquots of methanol followed by 2 
× 4 mL Milli-Q water. The samples were acidified on-site with 2 M hydrochloric acid (HCl) 
to adjust to pH 2 before on-site freezing at -20 oC to reduce microbial degradation of 
analytes. All wastewater influent samples were transported back to the laboratory where they 
were stored in the Australian Environmental Specimen Bank in the dark at below -20 
o
C until 
analysis. 
 
2.3. Solid-phase extraction optimisation 
 
Three commercially available SPE cartridges (details can be found in the S.I.), 
hydrophilic-lipophilic balanced (Oasis HLB), mixed-mode strong cation-exchange (Oasis 
MCX) and Sep-Pak AccellPlus CM (hydrophilic, weak cation-exchanger), were assessed for 
the recovery of analytes of interest, as well as their variability using two different elution 
methods of i) 100% methanol and ii) 5% ammonium hydroxide in methanol. As a pilot 
experiment, the three different sorbents were investigated using 10 mL ultrapure (Milli-Q) 
water spiked with native compounds at a concentration of 0.2 µg L
-1
. Two of the most 
suitable sorbents and their elution conditions were selected for further optimisation. Analyte 
recoveries were evaluated by spiking 10 mL aliquots of pooled wastewater influent samples 
  
This article is protected by copyright. All rights reserved. 
with either 0.2 µg L
-1
 native compounds before extraction (concentration factor = 50) or 200 
µL extract with 10 µg L
 -1
 native compounds (theoretical 100% recovery, n = 3 each). 
Recoveries were determined by comparing the response of the analyte spiked into the sample 
before extraction to the response of the analyte spiked into the extract. In this study, HLB was 
compared to MCX and to a combination (stacking) of HLB and MCX (HLB/MCX). HLB 
cartridges were eluted with methanol, whereas MCX and HLB/MCX cartridges were eluted 
with methanol and 5% NH4OH in methanol. 
 
2.4. Optimised sample preparation 
 
Acidified (pH2 adjusted with HCl) influent wastewater samples were defrosted and 
homogenised before 10 mL aliquots were spiked with isotopically labelled standards. 
Concentrations were as follows: 0.4 µg L
-1
 for DHEA-D5 and 0.1 µg L
-1
 for 5α-DHT-D3, 
androstene-3,17-dione-2,3,4-
13
C3, epitestosterone-D3, nandrolone-D3 and testosterone-D3. 
DHEA-D5 was spiked at a higher concentration due to its low sensitivity. Subsequently, the 
samples were filtered using 0.2 µm regenerated cellulose (RC) filters and subjected to SPE. 
The optimised SPE method involved conditioning MCX 3 mL x 60 mg cartridges with 3 
mL methanol followed by 2 x 1.5 mL Milli-Q water at pH 2. The cartridges were then loaded 
with 10 mL of spiked and filtered sample and washed with 3 mL Milli-Q and 70:30 Milli-
Q:methanol, both at pH 2 (acidified with HCl). Vacuum at ≤25 kPa was applied for 30 
minutes until the sorbent was dry, after which the compounds were eluted into polypropylene 
(PP) capped test tubes using 1 mL methanol followed by 2 mL 5% NH4OH in methanol. The 
extracts were concentrated using a gentle stream of N2 at 40 
o
C until 300 µL remained and 
transferred into a 2 mL amber vial. The PP capped test tubes were rinsed twice with 300 µL 
methanol, which was also transferred to the vial. The extracts were then further concentrated 
to dryness and reconstituted in 200 µL of 90:10 mobile phase A (0.2 mM ammonium fluoride 
(NH4F) in Milli-Q water):mobile phase B (95:5 (v/v) methanol/water). This was achieved by 
first adding 40 µL 50:50 A:B for an increased dissolution of organic matter, to which an 
additional 160 µL of aqueous mobile phase A was added using positive displacement 
pipettes. The final extracts were vortexed and stored at -20 
o
C until analysis. 
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2.5. Method development and instrumental analysis 
 
Direct infusion was used to select and optimise analyte transitions (instrument and 
parameters for analysis can be found in the S.I. Table S3). Declustering potential (DP), 
entrance potential (EP), collision energy (CE) and collision exit cell potential (CXP) were 
optimised for the individual transitions. Negative mode was also investigated (see Table S2 
for further details). Electrospray ionisation source temperatures were evaluated for 
optimisation of ionisation efficiency. 
Three different analytical columns were assessed for separation efficiency of the target 
analytes: Kinetex® Biphenyl 100 Å 50 x 2.1 mm 2.6 μm, Kinetex® F5 100 Å 50 x 2.1 mm 
2.6 μm and Kinetex® XB C18 100 Å 50 x 2.1 mm 1.7 μm (Phenomenex, Lane Cove West, 
NSW, AU). Multiple mobile phase compositions and additives were investigated for peak 
shape and ionisation efficiency. Additives for the mobile phase A tested included: 0.2 mM 
NH4F, 0.1% acetic acid and a combination of both. Different compositions of mobile phase B 
assessed were 50:50 (v/v) methanol/acetonitrile, 95:5 (v/v) methanol/water and 100% 
methanol. Mobile phase A was selected as 0.2 mM NH4F in Milli-Q water, mobile phase B as 
95:5 (v/v) methanol/water. 
Mobile phase B was set to 50% at the beginning of the gradient and increased linearly to 
95% until 8.50 min (see S.I. Table S3 for analysis parameters). This was kept constant until 
10.91 min where the concentration of mobile phase B was then decreased to 50% and 
equilibrated until the end of the analytical run at 14.10 min. Acquired data was processed 
utilising MultiQuant 3.0.2 software (Sciex). 
 
2.6. Method validation and stability assessment 
 
The method, including sample preparation, was validated according to The International 
Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 
(ICH) guidelines
38
. Methodology was evaluated for specificity, linearity, range, accuracy, 
precision, limit of detection (LOD), limit of quantification (LOQ), recovery and matrix effect 
by spiking and analysing pooled acidified wastewater influent. Calculations for analytes with 
an isotopically labelled analogue were based on the area ratio of native to isotopically 
labelled standard. All calculations for compounds for which an isotopically labelled standard 
was not available were based on peak area. For overall method linearity, a matrix-matched 
calibration curve was made up by spiking pooled wastewater with different concentrations of 
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native analytes (N = 9, ranging from 0.002–1 µg L-1) and a fixed concentration of six labelled 
internal standards (as described in 2.3.) and subjected to the extraction procedure. A second 
calibration curve in 90:10 mobile phase A:mobile phase B was prepared in the same manner 
to test instrumental method linearity. Linearity for each analyte was determined using a 
weighting of 1/x. The range was determined for each analyte where R
2
 ≥ 0.99 and N ≥ 5. 
Accuracy and precision were calculated at three different concentrations (0.05 µg L
-1
, 0.2 µg 
L
-1
 and 0.4 µg L
-1
) with at least three determinations at each concentration. LOD and LOQ 
were determined for each analyte at the lowest available concentration from the calibration 
curve at which both quantifier and qualifier (with an ion ratio of ≤30%) were detected. The 
standard deviation of the measured response (n = 7) was multiplied by 3.3 (LOD) and 10 
(LOQ) which was then divided by the slope of the matrix-matched calibration curve. The 
relative matrix effect (%) was assessed by dividing the slope of the matrix-matched 
calibration curve by the slope of the calibration curve in 90:10 A:B multiplied by 100. In 
addition, concentration dependent matrix effects were determined by dividing the background 
corrected response of the analyte spiked into the extract after SPE (0.2 µg L
-1
, n = 6) with the 
response of the analyte spiked at the same concentration into 90:10 A:B. 
 A 24-hour stability assessment of all analytes in acidified wastewater influent was 
conducted to determine if stability is of concern for the target analytes. A volume of 1 mL 
wastewater influent was spiked with native standards (10 µg L
-1
) and internal standards (5 µg 
L
-1
 and 20 µg L
-1
 for DHEA-D5) and directly filtered into an amber vial (n = 3). This was 
done immediately before the sample was put into the LC autosampler, set to 22 °C, and 
injected (to analyse sample at t0). Additionally, 1 mL of unspiked, filtered wastewater 
influent was analysed. A calibration curve in ultrapure water at pH 2 (HCl acidified) was 
prepared and analysed to determine the initial concentration and subsequently the percentage 
of initial concentration (%). Samples were analysed every hour for the first six hours, after 
which they were injected every 2-3 hours. Photodegradation was excluded from this study as 
the samples were in amber vials and analysed in a closed autosampler. 
 
2.7. Targeted analysis of AAS 
 
 Acidified wastewater influent samples from two different wastewater treatment plants 
(WWTPs) in Australia were selected for targeted analysis of AAS and hormones of interest. 
For WWTP A, four consecutive days were selected based on the occurrence of a 
bodybuilding event. The first day was the day before the event, the next two during the event 
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and the fourth day was after the event. The four samples were extracted and analysed in 
triplicate as described in section 2.4. A matrix-matched calibration curve (external 
calibration) was generated by pooling samples of nine consecutive days from WWTP A, 
including samples from the four days selected for targeted analysis. 
 A second wastewater treatment plant (WWTP B) was chosen based on its coastal and 
metropolitan features. One 24-hour composite sample per season (February, May, August and 
November) was randomly selected for three different years (2013, 2015 and 2017). The same 
aliquots of all twelve samples were pooled to create a matrix-matched calibration curve. 
Samples were analysed in triplicate. 
It is generally not possible to obtain wastewater influent free of analyte that can be used to 
generate a matrix-matched calibration curve. Due to limited volume availability of influent 
wastewater samples, multiple 24-hour composite samples from the same WWTP were pooled 
to create sufficient volume for a nine-point matrix-matched calibration curve, as the matrix 
was assumed to be sufficiently similar within the same WWTP. Both external matrix-
matched calibration curves were prepared by spiking with native standards at nine 
concentrations ranging from 0.002 – 0.4 µg L-1 and internal isotopically labelled standards at 
a concentration of 0.1 µg L
 -1
 (0.4 µg L
 -1
 for DHEA-D5). For the six compounds with a 
labelled analogue, the isotope dilution method was used for quantitation. This was achieved 
by spiking 10 mL of the sample with internal standards at the same concentration as in the 
external calibration curve. Peak area ratios of internal standard in the sample and calibration 
curve were used to calculate the concentration of the analyte in triplicate samples. The 
concentrations of all other analytes were calculated using their response in sample compared 
to their response in the external matrix-matched calibration curve. The calculation subtracted 
the background concentration of analytes. All samples, including calibration curves, were 
subjected to the extraction procedure. For quality control purposes, 10 mL of the pooled 
wastewater influent from each WWTP was filtered and extracted. This involved both 
background subtraction of any analyte present in the pooled sample for calibration accuracy, 
but also to check whether any SRM transitions interfered with those of the isotopically-
labelled standards (for the latter, none were present). In addition, 10 mL of ultrapure water at 
pH 2 was filtered, extracted and analysed to show if any contamination occurred during the 
preparation or analysis procedure. Ultrapure water containing 0.2 mM NH4F (mobile phase 
A) was analysed between each sample set and no carry-over was observed. Analytes 
identified by their quantifier ion were confirmed using retention time and a second transition 
(qualifier ion) with an ion ratio of ≤30%. 
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 Excretion mass loads of analytes 1000 individuals
-1
 were estimated using concentration, 
flow and population data, using the method presented by Lai et al
39
, based on an approach by 
Zuccato et al
24
. The equation used was as follows: normalised excretion mass load = 
(concentration x flow)/(number of people
 
1000
-1
). Flow and population data were available 
for every sample collected from WWTP A and were provided by the wastewater treatment 
plant authorities. Exact flow data was not available for the chosen dates of WWTP B, 
therefore an average flow was calculated based on data collected from multiple years. This 
was deemed acceptable, as the daily flow rates were quite consistent (%RSD = 8). 
3.  
4. Results and discussion 
 
3.1. Method development and optimisation 
 
  Of the SPE cartridges tested, MCX was the best as it demonstrated acceptable analyte 
recovery (80-120%) and showed lower variability (Figure 1) and ion suppression than HLB 
(further details in S.I.). Sep-Pak AccellPlus CM had very poor recoveries (<20%) for the 
compounds of interest. 
Comparison of the LC columns found that the best separation of all analytes of interest was 
achieved on the Kinetex® XB C18 column (example chromatogram in Figure 2) when 
compared to F5 and biphenyl stationary phases (see S.I. for further details). Best peak shape 
and ionisation efficiency were achieved with addition of 0.2 mM NH4F to mobile phase A 
and using 95:5 (v/v) methanol/water as mobile phase B. During compound parameter 
optimisation, it was decided to exclude oxymetholone from further analysis due to poor 
ionisation efficiency and peak width (>30 seconds). 
 
3.2. Method validation and stability assessment 
 
 A total of 24 steroids and hormones were subjected to method validation of which 
seven (four AAS and three hormones) did not fulfil the guideline requirements. These 
compounds were boldenone, equilin, mestranol, oxandrolone, stanozolol, trenbolone and 
estriol. Stanozolol showed an insufficient accuracy of 63% at a concentration of 0.3 µg L
-1
 
(data not shown), whereas trenbolone and estriol demonstrated accuracies of 20% and 50%, 
respectively, at 0.05 µg L
-1
. It should be emphasised however, that the accuracy for estriol at 
0.05 µg L
-1
 was determined near the LOQ of 0.04 µg L
-1
. Mestranol demonstrated 
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unsatisfactory linearity (R
2
 < 0.99). Boldenone, equilin and oxandrolone also did not pass 
method validation due to insufficient linearity, which may have been caused by interferences 
observed (see below) and these analytes were therefore excluded from targeted analysis. 
However, the other analytes that did not pass method validation were included in the analysis 
for semi-quantitative purposes. Precision for all analyte retention times were within an 
acceptable range (0.00-0.16 %RSD). Recoveries were satisfactory with values between 77–
117% with the exception of drostanolone and progesterone, which had recoveries of 66% and 
68%, respectively. All analytes that passed method validation had accuracies of 84–109% 
across all three concentrations, with acceptable relative standard deviations of <1–7%. 
Exceptions were 17α-ethynylestradiol, 17β-estradiol and estrone, which had %RSD values of 
up to 15%. Relative matrix effects varied greatly between compounds, although all were 
affected by ion suppression as opposed to enhancement. Compared to other LC-MS methods 
that were used to investigate AAS in matrix, this method shows similar to increased precision 
and lower LODs/LOQs leading to increased sensitivity 
26,28
. This shows that the developed 
method is suitable for the intended purpose of analysing AAS in wastewater. The method 
performance data for each analyte is listed in Table 1. 
 
Selectivity 
 
 Method validation highlighted the possibility for the occurrence of interfering compounds 
during analysis. Several monitored transitions exhibited interferences due to shared structural 
similarity and could therefore not be validated with the applied method. Both selected 
reaction monitoring (SRM) transitions chosen for boldenone suffered from matrix 
interference. An unknown interfering compound detected in wastewater influent had a 
retention time (3.72 min) very similar to that of boldenone (3.68 min). Subsequently, three 
additional transitions were added to the analysis (m/z 287.1 → 269.1, m/z 287.1 → 199.1 and 
m/z 287.1 → 91.1), which again were all shared by the unknown compound, but with 
different ion ratios compared to boldenone. The interference was not seen in ultrapure water 
spiked with native boldenone, but was detected in all unspiked, extracted wastewater influent 
samples showing the highest intensity of all analytes detected. The identification of the 
interfering compound was outside the scope of this study. All three transitions selected for 
equilin (m/z 269.1 → 211.1, m/z 269.1 → 157.1 and m/z 269.1 → 152.1) were also shared 
with interfering compounds in wastewater influent in a similar way. Transitions for 
oxandrolone were subject to the same issue. Some transitions had interferences which were 
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minor and could therefore still be used as qualifier ions without any issues. Analyte 
transitions affected were DHEA m/z 271.1 → 253.1, fluoxymesterone m/z 337.2 → 181.1, 
methandienone m/z 301 → 149, progesterone m/z 315.1 → 97.1, stanozolol m/z 329.1 → 
121.1 and tetrahydrogestrinone m/z 313.1 → 159.1. All analytes that passed method 
validation had selective quantifier ion transitions. 
 
Stability assessment 
 
The majority of analytes did not demonstrate significant degradation over a 24-hour period 
at 22 
o
C in acidified and filtered wastewater influent. Interestingly, all four hormones 
analysed in negative ESI mode showed a slight decline in initial concentration (15%) over 
the 24-hour time period (S.I., Figure S2). In-sewer degradation was outside the scope of this 
study.  
 
3.3. Occurrence of AAS in Queensland wastewaters over 2013-2017 
 
 3.3.1. WWTP A 
 
 Analysis of 24-hour composite influent wastewater samples from four consecutive days 
revealed eight hormones and metabolites to be present in all samples at concentrations 
ranging between 15–611 ng L-1 (Table 2). Estimated excreted mass loads are presented in 
Figure 3. These eight compounds were 5α-dihydrotestosterone, androstenedione, 
epitestosterone, estriol, estrone, progesterone, testosterone and β-estradiol. No other 
hormones were detected in any of the four samples. Estriol was determined to be semi-
quantitative due to an accuracy value of 50% at 0.05 µg L
-1
, however it is to be noted that 
estriol was found to be present at concentrations of up to 0.6 µg L
-1
 relating to the highest 
mass load (76–104 mg day-11000 individuals-1). Accuracy values for estriol at this level were 
satisfactory (see Table 1). Epitestosterone (6–7 mg-1day-11000 individuals-1), progesterone 
(6–11 mg day-11000 individuals-1), testosterone (5–7 mg day-11000 individuals-1) and -
estradiol (3–6 mg day-11000 individuals-1) showed the lowest mass load values in this 
catchment. The testosterone/epitestosterone ratio (T/E ratio) during all four days was ~1:1 
suggesting no significant population scale use of exogenous hormones, according to WADA 
requirements
17
. No AAS were detected in the samples collected during the bodybuilding 
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event. Further research may show that metabolites and/or transformation products may be 
more reliable target compounds but was beyond the scope of this work. Also, due to their 
moderate hydrophobicity, AAS and metabolite concentrations might be higher in biosolids, 
which has been investigated for similar compounds
40,41
 but requires further research. The 
matrix of WWTP A differed from the matrix observed in other analysed pooled wastewater 
influent samples. The signal-to-noise ratio for all peaks analysed was decreased due to a 
higher general background level. The increased background might be due to WWTP A 
having about half the population size, but roughly only 25% of the flow rate compared to the 
wastewater treatment plant from which samples were pooled and analysed for method 
validation and the sample preparation experiments. 
 
 3.3.2. WWTP B 
 
 Analysis of twelve wastewater influent samples from WWTP B covering three years and 
four seasons revealed that steroids, metabolites and hormones were detected at concentrations 
ranging from 2 to 204 ng L
-1. These included 5α-dihydrotestosterone, androstenedione, 
DHEA, epitestosterone, estriol, estrone, progesterone, stanozolol, testosterone and β-estradiol 
(Table 2). The AAS stanozolol was detected in one of the samples but could not be quantified 
(<LOQ). The detection of stanozolol is significant, as it shows that WBE may emerge as a 
tool for monitoring trends in the use of these chemicals. Stanozolol was targeted as the parent 
compound only and the conjugated metabolites might be higher in abundance. However, the 
deconjugation in sewer is unknown. Therefore, enzymatic hydrolysis could be investigated 
when targeting the parent compound to deconjugate the analyte, increasing the concentration 
of the free parent compound. 
The mass load of androstendione was calculated to be 26-66 mg day
-1
1000 individuals
-1
, 
which correlates to excretion values found in the literature
42
. When transforming those values 
into excretion mass loads (assuming 50:50 women:men in the catchment), values ranging 
between 18 and 62 mg day
-1
1000 individuals
-1
 were determined, which are consistent with 
the excretion mass loads as stated above. It is important to note that there are uncertainties 
when calculating consumption and/or excretion mass loads, including sampling
43
, flow 
measurement, excretion data, number of people contributing to the wastewater samples
44
 and 
potential for in-sewer instability
45
. In addition, the wastewater influent sample from 
November 2013 was considered an outlier due to very low levels and was excluded from 
excretion mass load calculations. 
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5. Conclusion 
 
A selective and sensitive analytical method for AAS, hormones and metabolites in influent 
wastewater was developed and validated for 17 compounds of interest. In application of the 
method, nine investigated compounds were quantified in multiple 24-hour composite samples 
from two Queensland wastewater treatment plants. These were found to be present at 
concentrations of between 14 and 611 ng L
-1
 translating to excretion mass loads of 3 to 104 
mg day
-1
1000 individuals
-1
. The quantified compounds were 5α-dihydrotestosterone, 
androstenedione, dehydroepiandrosterone, epitestosterone, estrone, progesterone, 
testosterone, β-estradiol, and semi-quantitative for estriol. Furthermore, the AAS stanozolol 
was detected in one wastewater influent sample. Future studies could investigate the addition 
of deconjugation steps to increase the concentration of parent drugs in wastewater samples. In 
addition, AAS metabolites or transformation products could be assessed for suitability within 
the WBE approach. The latter presents great research potential, as the information available 
in the literature on metabolites and transformation products is scarce. Finally, as steroids and 
hormones are known to be moderately hydrophobic, an additional investigation into biosolids 
may be worth pursuing. This first study in Australia will serve as an important reference point 
for global level WBE-based assessment of AAS. 
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Table 1. LC-ESI-MS/MS method performance data for steroids and hormones in pooled wastewater influent using ICH guidelines38. 
Analyte MRM 
transitionsa 
ESI 
mode 
tr (min) ± 
%RSD 
%Average 
Recovery  
± SD 
%Accuracy ± %RSD (N = 3) LOD 
(ng L-1) 
LOQ 
(ng L-1) 
Linearity 
(R2) 
Range (µg L-1) %Relative 
matrix 
effectb,d 
%Matrix 
effect ± 
SDc,d 
 m/z  (n = 9) (n = 6) (n = 7) (n = 6) (n = 3) (n = 7) (n = 7)     (n = 6) 
      0.2 µg L-1 0.2 µg L-1 0.05 µg L-1 0.2 µg L-1 0.4 µg L-1             0.2 µg L-1 
5α-Dihydrotestosterone* 291.1 → 255.1 
291.1 → 159.1 
+ 5.46 ± 0.06 104 ± 2 90 ± 5 91 ± 2 92 ± 1 3.0 9.1 0.995 (0.003-1) (N = 9) -32 -31 ± 6 
17α-Methyltestosterone 303.1 → 109.1 
303.1 → 267.1 
+ 5.06 ± 0.12 83 ± 3 99 ± <1 96 ± 3 95 ± <1 0.4 1.1 0.998 (0.002-1) (N = 9) -26 -17 ± 5 
19-Norethindrone 299.1 → 231.1 
299.1 → 115.1 
+ 4.04 ± 0.12 88 ± 4 89 ± 3 101 ± 4 97 ± 1 8.3 25.3 0.998 (0.013-1) (N = 7) -33 -23 ± 6 
Androstenedione* 287.1 → 97.1 
287.1 → 109.1 
+ 3.97 ± 0.12 111 ± 2 94 ± 3 98 ± 2 100 ± 1 3.3 10.0 0.996 (0.003-1) (N = 9) -32 -32 ± 3 
Boldenone 287.1 → 121.1 
287.1 → 135.1 
+ 3.68 ± 0.09 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
D(-)-Norgestrel 313.1 → 245.1 
313.1 → 109.1 
+ 5.03 ± 0.06 78 ± 3 95 ± <1 95 ± 4 96 ± <1 0.3 0.8 0.999 (0.006-1) (N = 8) -33 -19 ± 5 
Dehydroepiandrosterone* 271.1 → 213.1 
271.1 → 253.1 
+ 4.71 ± 0.15 117 ± 3 92 ± 3 98 ± 3 101 ± 2 6.4 19.5 0.993 (0.006-1) (N = 7) -28 -36 ± 14 
Drostanolone 305.1 → 215.1 
305.1 → 269.1 
+ 6.50 ± 0.10 66 ± 3 96 ± 2 96 ± 5 98 ± 4 1.1 3.4 0.999 (0.013-1) (N = 8) -52 -28 ± 1 
Epitestosterone* 289.1 → 97.1 
289.1 → 109.1 
+ 5.38 ± 0.06 106 ± 1 93 ± 1 96 ± 1 97 ± 2 0.5 1.5 0.997 (0.002-1) (N = 9) -27 -21 ± 4 
Equilin 269.1 → 211.1 
269.1 → 157.1 
+ 3.62 ± 0.13 n.d. n.d. n.d. n.d. n.d. n.d. 0.970 n.d. (N = 5) -49 n.d. 
Fluoxymesterone 337.2 → 241.1 
337.2 → 181.1 
+ 3.61 ± 0.09 93 ± 3 93 ± 2 97 ± 3 95 ± <1 1.7 5.3 0.999 (0.013-1) (N = 7) -29 -28 ± 4 
Mestranol 311.2 → 121.1 
311.1 → 159.1 
+ 7.18 ± 0.07 n.d. n.d. n.d. n.d. n.d. n.d. 0.999 n.d. (N = 5) -77 n.d. 
Methandienone 301.1 → 121.1 
301.1 → 149.1 
+ 4.24 ± 0.16 92 ± 3 93 ± 1 97 ± 3 96 ± 1 0.8 2.3 0.998 (0.006-1) (N = 8) -27 -25 ± 6 
Nandrolone* 275.1 → 109.1 
275.1 → 239.1 
+ 3.87 ± 0.08 100 ± 1 96 ± 1 95 ± 1 98 ± 1 0.6 1.9 0.997 (0.006-1) (N = 8) -32 -26 ± 2 
Oxandrolone 307.1 → 229.1 
307.1 → 271.1 
+ 3.88 ± 0.16 n.d. n.d. n.d. n.d. n.d. n.d. 0.972 n.d. (N = 5) -60 n.d. 
Progesterone 315.1 → 109.1 
315.1 → 97.1 
+ 6.13 ± 0.08 68 ± 6 86 ± 1 97 ± 6 99 ± 1 0.4 1.3 0.998 (0.002-1) (N = 9) -50 -28 ± 1 
Stanozolol 329.1 → 203.1 
329.1 → 121.1 
+ 6.40 ± 0.10 109 ± 6 81 ± 4 88 ± 6 106 ± 6 2.2 6.8 0.990 (0.05-1) (N = 5) -78 - 81 ± 2 
Testosterone* 289.1 → 97.1 + 4.47 ± 0.15 99 ± 1 88 ± 1 95 ± 1 96 ± <1 0.5 1.4 0.998 (0.002-1) (N = 9) -27 -21 ± 4 
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289.1 → 109.1 
Tetrahydrogestrinone 313.1 → 241.1 
313.1 → 159.1 
+ 5.82 ± 0.05 77 ± 5 96 ± <1 100 ± 6 98 ± 2 0.3 0.9 0.999 (0.002-1) (N = 9) -46 -33 ± 1 
Trenbolone 271.1 → 199.1 
271.1 → 227.1 
+ 3.32 ± 0.13 80 ± 5 20 ± 1 95 ± 6 98 ± 1 0.5 1.5 0.999 (0.006-1) (N = 8) -43 -34 ± 3 
17α-Ethynylestradiol 295.1 → 145.1 
295.1 → 143.1 
- 4.05 ± 0.10 92 ± 13 <LOQ1 91 ± 14 91 ± 2 23.7 71.7 0.992 (0.025-1) (N = 6) -42 -40 ± 17 
17β-Estradiol 271.1 → 145.1 
271.1 → 183.1 
- 3.90 ± 0.08 96 ± 11 84 ± 8 101 ± 12 100 ± 3 4.2 12.6 0.999 (0.004-1) (N = 9) -41 -47 ± 7 
Estriol 287.1 → 171.1 
287.1 → 145.1 
- 1.15 ± 0.00 96 ± 5 50 ± 8 105 ± 5 97 ± 1 14.7 44.4 0.996 (0.015-1) (N = 9) -48 -45 ± 4 
Estrone 269.1 → 145.1 
269.1 → 143.1 
- 3.89 ± 0.08 95 ± 15 85 ± 7 109 ± 15 102 ± 1 10.5 31.8 0.991 (0.011-1) (N = 9) -38 -35 ± 5 
SD = standard deviation, RSD = relative standard deviation            
n = replicate number at same concentration, N = replicate number at different concentrations         
n.d. = not determined               
LOD = limit of detection, LOQ limit of quantification             
*Calculations based on area ratio due to use of isotopically labelled analogue 
a Transitions in bold font represent the quantifier ion for each analyte. The second transition represents the qualifier ion.  
    
b Defined as: ((slope of matrix-matched calibration curve/slope of extract solvent calibration curve)*100)-100        
c Defined as: ((background corrected response of analyte spiked into extract/response of analyte spiked into extraction solvent)*100)-100     
d LC-ESI-MS signal suppression (-) or enhancement (+) 
1 To satisfy ICH guidelines, %Accuracy (96) and %RSD (11) were determined at a third concentration (0.3 µg L-1, n = 6)  
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Table 2. Concentrations of steroids and hormones in wastewater influent from two WWTPs in ng L-1. 
Compound WWTP A WWTP B 
 
Day 1 Day 2 Day 3 Day 4 2013 2015 2017 
     (n = 3)     Feb May Aug Nov Feb May Aug Nov Feb May Aug Nov 
17α-Ethynylestradiol* - - - - - - - - - - - - - - - - 
17α-Methyltestosterone - - - - - - - - - - - - - - - - 
19-Norethindrone - - - - - - - - - - - - - - - - 
5α-Dihydrotestosterone 152-168 117-133 162-165 180 59-61 65-66 70-72 - 89-92 70-72 78-80 91-93 88-95 77-80 82-83 108-112 
Androstenedione 192-196 165-170 141 169-175 160-161 162 158-159 <LOQ 203-204 146-147 146-147 183-185 119-121 173-175 156-157 122-123 
D(-)-Norgestrel - - - - - - - - - - - - - - - - 
Dehydroepiandrosterone - - - - 97-106 118-123 133-139 <LOQ 116-129 95-97 96-98 134-137 115-116 111-115 110-119 111-113 
Drostanolone - - - - - - - - - - - - - - - - 
Epitestosterone 36-37 34 30 37-39 14-15 15 16 - 18 15 15-16 18 16 21-22 23-24 19 
Estriol* 549-611 382-469 514-562 561-609 62-67 71-75 84-87 <LOQ 102-108 82-85 91-97 97-101 118-122 149-155 194-197 176-179 
Estrone 158-190 116-124 69-79 78-83 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ -48 46-47 46-49 47-49 48-50 
Fluoxymesterone - - - - - - - - - - - - - - - - 
Mestranol* - - - - - - - - - - - - - - - - 
Methandienone - - - - - - - - - - - - - - - - 
Nandrolone - - - - - - - - - - - - - - - - 
Progesterone 46-48 35 30-32 59-63 45 28 33 2 29 33 32-33 32 20 14-15 10-11 18-19 
Stanozolol* - - - - - - - - - - - - - <LOQ - - 
Testosterone 40-41 28-30 26-27 33-34 14 15 19 <LOQ 22 17 18 20 14 19-20 20 15 
Tetrahydrogestrinone - - - - - - - - - - - - - - - - 
Trenbolone* - - - - - - - - - - - - - - - - 
β-Estradiol 31-37 23-26 15-19 23-24 <LOQ <LOQ <LOQ - <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
- = not detected (<LOD) 
* did not pass method validation – included for semi-quantitative purposes 
Boldenone, equilin and oxandrolone were excluded due to selectivity issues 
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Figure 1. Performance comparison of different SPE sorbents showing min to max and median of n = 
3. Graph depicts recovery values (%) for analytes and each sorbent investigated. 
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Figure 2. Extracted ion chromatogram (XIC) showing quantifier ion transitions for AAS and hormones 
of interest in ultrapure water at a concentration of 10 µg L-1. (a) Compounds analysed in positive ESI 
mode. (b) Hormones analysed in negative ESI mode. 
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Figure 3. Calculated excreted mass load in mg day-11000 people-1. Bars that are not present indicate 
a concentration below LOQ. Bars in grey represent excretion mass load values for samples collected 
from WWTP A. Black bars depict excretion mass load values from samples collected from WWTP B. 
Error bars show standard deviation (n = 3). 
 
 
